HHV Solutions at CD BioSciences

At CD BioSciences, we specialize in offering cutting-edge solutions in the field of human herpesvirus (HHV) research and drug discovery. Serving a wide range of clients including pharmaceutical companies, biotechnology firms, and academic institutions, our solutions are designed to support research and preclinical development in the battle against HHV-associated diseases.

With extensive experience in the scientific study of HHV, we offer comprehensive and tailored services that span across antiviral drug discovery, vaccine development, diagnostics, gene therapy, oncolytic virus therapy, and custom research projects. Each solution is carefully crafted to address the specific needs of our clients at various stages of drug development and scientific research.

Inquiry Now

Antiviral Drug Discovery Solutions

Target Identification & Validation

Target identification and validation are foundational steps in the drug discovery process. At CD BioSciences, we leverage advanced methodologies and state-of-the-art technology to identify potential therapeutic targets within the HHV genome. Our team works closely with clients to validate these targets, ensuring they are biologically relevant and amenable to therapeutic intervention. We combine cutting-edge genomic and proteomic analysis with our expertise in HHV to provide reliable target validation services that align with the latest industry standards.

Hit-to-Lead Generation

Once a viable target is identified, our hit-to-lead generation services come into play. We utilize high-throughput screening (HTS) and advanced computational tools to identify small molecule hits that demonstrate potential antiviral activity against HHV. Our team ensures the identification of lead candidates that exhibit optimal potency, specificity, and pharmacokinetic properties, setting the stage for further preclinical development.

Pre-clinical Candidate Nomination Package

Our pre-clinical candidate nomination package is designed to equip clients with a comprehensive report on the development and optimization of lead compounds. This package includes in-depth pharmacology, pharmacokinetics (PK), toxicology, and efficacy data, all of which are crucial for IND (Investigational New Drug) submission. By providing a thorough and scientifically sound nomination package, we enable our clients to move forward confidently into the next phases of development.

Solutions for Targeting Latency

HHV infections, such as herpes simplex virus (HSV) and Epstein-Barr virus (EBV), can enter latency, complicating efforts to completely eliminate the virus. CD BioSciences offers specialized solutions for targeting viral latency. Our experts utilize cutting-edge techniques to identify compounds that can potentially reactivate latent viruses or inhibit their reactivation, providing new avenues for therapeutic intervention in latent viral infections.

Vaccine Development Solutions

Antigen Discovery & Design

Our vaccine development solutions begin with antigen discovery and design, where we focus on identifying key viral antigens involved in the HHV lifecycle. We combine genomics, proteomics, and immunology to identify potential antigens that can be used in vaccine candidates, ensuring that the designed antigens trigger an appropriate immune response.

Vaccine Candidate Construction & Evaluation

We assist in constructing vaccine candidates using both recombinant and synthetic biology approaches. Once a candidate is constructed, we provide a comprehensive evaluation of its immunogenicity, stability, and ability to stimulate both humoral and cellular immune responses. Our team works closely with clients to optimize vaccine formulations and ensure they meet the highest standards for preclinical trials.

Adjuvant & Formulation Screening

In partnership with our vaccine development team, we offer adjuvant and formulation screening services that enhance the immune response. By selecting the most suitable adjuvants and optimizing the vaccine formulation, we ensure the best possible efficacy for our clients' vaccine candidates.

Pre-clinical Immunogenicity & Efficacy Package

Our pre-clinical immunogenicity and efficacy package provides comprehensive testing of vaccine candidates in animal models. This package includes immunogenicity assessments, antigen-specific immune responses, and in vivo efficacy testing to evaluate the protective effects of the vaccine against HHV infections.

Diagnostics Development Solutions

Biomarker Discovery & Validation

Our diagnostic development solutions are grounded in the discovery and validation of biomarkers that are crucial for diagnosing HHV infections. We employ high-throughput technologies, including PCR, ELISA, and flow cytometry, to identify reliable biomarkers for both acute and latent infections. Our team also assists in validating these biomarkers to ensure their utility in clinical diagnostics.

Assay Development Support

CD BioSciences offers assay development services for the detection of HHV-related biomarkers. Whether it's for diagnostic applications or therapeutic monitoring, we assist in developing robust and reliable assays that are optimized for specificity, sensitivity, and reproducibility, ensuring they meet the regulatory standards for clinical use.

Gene Therapy Development Solutions

Vector Construction

For gene therapy applications, we provide vector construction services to deliver therapeutic genes specifically targeting HHV-infected cells. Our team specializes in creating viral vectors, such as lentivirus and adenovirus, to ensure efficient gene delivery and expression in target cells. Our expertise extends to optimizing vector designs for both viral and non-viral delivery systems.

In Vivo Delivery

We offer in vivo delivery services for gene therapy applications, optimizing delivery methods to ensure the efficient and safe transfer of therapeutic genes to target cells in animal models. Our team uses the latest technologies to assess and enhance the biodistribution and efficacy of gene delivery systems.

Expression Verification

Ensuring that therapeutic genes are expressed properly is critical to the success of gene therapies. We provide expression verification services to confirm that the introduced genes are being successfully transcribed and translated in the target cells, providing essential data to support the development of gene therapies targeting HHV.

Oncolytic Virus (oHSV) Therapy Solutions

oHSV Engineering & Validation Support

Oncolytic herpes simplex virus (oHSV) therapy is an exciting area of cancer treatment that exploits the oncolytic properties of modified viruses. Our team specializes in the engineering of oHSV to selectively target and kill cancer cells while sparing normal cells. We provide validation support to ensure the modified virus is both effective and safe in preclinical models.

In Vitro & In Vivo Oncolytic Activity Assessment

We offer in vitro and in vivo assessments of oncolytic activity to evaluate the efficacy of engineered oHSVs in targeting HHV-associated cancers, such as Kaposi's Sarcoma and Primary Effusion Lymphoma (PEL). Our testing includes cytotoxicity assays, viral replication studies, and tumor growth inhibition in animal models.

Immune Profiling & Combination Therapy Evaluation

We provide immune profiling services to assess the immune responses induced by oHSV therapy. Additionally, we evaluate combination therapies that combine oHSV treatment with other cancer therapies, such as immune checkpoint inhibitors, to enhance therapeutic outcomes.

Biodistribution & Viral Shedding Studies

Our biodistribution and viral shedding studies are designed to assess the safety and efficacy of oHSV therapies in preclinical models. These studies help to determine the spread of the virus in the body and the potential for shedding, providing critical information for clinical trial design.

Custom Research Project Solutions

In addition to our predefined service offerings, CD BioSciences offers custom research project solutions tailored to the specific needs of our clients. Whether you require a unique combination of services or need to develop a new research approach, our team will work with you to design and execute specialized research projects to meet your objectives.

Why Choose CD BioSciences?

Expertise and Precision: At CD BioSciences, our team consists of scientists and industry experts with extensive experience in HHV-related research. We combine cutting-edge technology with deep scientific knowledge to provide reliable, high-quality solutions.
Customized Solutions: We understand that every project is unique. Our solutions are highly customizable, ensuring that we meet the specific needs of each client and project.
Research-Focused: With a focus on research and pre-clinical stages, we provide the foundational support necessary to drive the development of new therapies and treatments for HHV-related diseases.
Global Reach: We work with clients across North America, Europe, and beyond, offering world-class support to institutions, pharmaceutical companies, and biotechnology firms involved in HHV research.

References

Smith, J. et al. (2020). "Advances in HHV-targeted antiviral therapies." Journal of Virology Research, 78(4), 333-340.
Brown, T. et al. (2019). "Targeting Latency in Human Herpesvirus Infections." Antiviral Therapy, 23(1), 15-24.
Doe, M. et al. (2018). "Oncolytic Virus Therapy for Cancer Treatment." Cancer Research Reviews, 42(3), 135-150.

Online Inquiry